JP7687964B2 - 化合物、組成物、および使用方法 - Google Patents

化合物、組成物、および使用方法 Download PDF

Info

Publication number
JP7687964B2
JP7687964B2 JP2021569396A JP2021569396A JP7687964B2 JP 7687964 B2 JP7687964 B2 JP 7687964B2 JP 2021569396 A JP2021569396 A JP 2021569396A JP 2021569396 A JP2021569396 A JP 2021569396A JP 7687964 B2 JP7687964 B2 JP 7687964B2
Authority
JP
Japan
Prior art keywords
mmol
compound
pharma
piperidine
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021569396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533436A (ja
JP2022533436A5 (https=
Inventor
アレン テイラー ホッパー，
スティーブン ミシュク，
ダニエル ラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2022533436A publication Critical patent/JP2022533436A/ja
Publication of JP2022533436A5 publication Critical patent/JP2022533436A5/ja
Priority to JP2025037274A priority Critical patent/JP2025090698A/ja
Application granted granted Critical
Publication of JP7687964B2 publication Critical patent/JP7687964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021569396A 2019-05-24 2020-05-24 化合物、組成物、および使用方法 Active JP7687964B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025037274A JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962852565P 2019-05-24 2019-05-24
US62/852,565 2019-05-24
PCT/US2020/034434 WO2020243027A1 (en) 2019-05-24 2020-05-24 Compounds, compositions, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025037274A Division JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Publications (3)

Publication Number Publication Date
JP2022533436A JP2022533436A (ja) 2022-07-22
JP2022533436A5 JP2022533436A5 (https=) 2023-05-31
JP7687964B2 true JP7687964B2 (ja) 2025-06-03

Family

ID=71078654

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021569396A Active JP7687964B2 (ja) 2019-05-24 2020-05-24 化合物、組成物、および使用方法
JP2025037274A Pending JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025037274A Pending JP2025090698A (ja) 2019-05-24 2025-03-10 化合物、組成物、および使用方法

Country Status (7)

Country Link
US (1) US20220332699A1 (https=)
EP (1) EP3976186A1 (https=)
JP (2) JP7687964B2 (https=)
AR (1) AR119010A1 (https=)
MA (1) MA56032A (https=)
TW (2) TW202523658A (https=)
WO (1) WO2020243027A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2848212C (en) 2011-09-08 2022-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
SMT202200300T1 (it) 2016-04-01 2022-09-14 Sage Therapeutics Inc Ossisteroli e relativi metodi d'uso
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
IL309208A (en) 2021-06-11 2024-02-01 Sage Therapeutics Inc Neuroactive steroid for the treatment of alzheimer's disease
CN113501787A (zh) * 2021-08-20 2021-10-15 黑龙江省科学院石油化学研究院 一种合成6-三氟甲基-3-甲基吲唑的方法
US20240189312A1 (en) * 2022-12-02 2024-06-13 Morehouse School Of Medicine Composition for treating acute brain injury or neurodegenerative disease, method of making, and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504613A (ja) 2009-09-16 2013-02-07 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
JP2013527162A (ja) 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類
WO2014092100A1 (ja) 2012-12-11 2014-06-19 武田薬品工業株式会社 複素環化合物
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
JP2014528904A (ja) 2011-10-07 2014-10-30 武田薬品工業株式会社 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854204A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
JP2001500852A (ja) 1996-08-27 2001-01-23 プレーシス ファーマスーティカルズ インコーポレイテッド Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
US20100152160A1 (en) * 2008-12-12 2010-06-17 Khamrai Uttam Novel benzodioxane and benzoxazine derivatives useful as cc chemokine receptor ligands
MX2022003845A (es) * 2019-09-30 2022-06-22 Actinogen Medical Ltd Tratamientos cognitivos medicinales.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504613A (ja) 2009-09-16 2013-02-07 ザ ユニバーシティ オブ エディンバラ （４−フェニル−ピペリジン−１−イル）−［５−（１ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン化合物及びそれらの使用
JP2013527162A (ja) 2010-04-29 2013-06-27 ザ ユニバーシティ オブ エディンバラ １１β−ＨＳＤ１の阻害剤としての３，３−二置換−（８−アザ−ビシクロ［３．２．１］オクタ−８−イル）−［５−（１Ｈ−ピラゾール−４−イル）−チオフェン−３−イル］−メタノン類
JP2014528904A (ja) 2011-10-07 2014-10-30 武田薬品工業株式会社 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物
WO2014092100A1 (ja) 2012-12-11 2014-06-19 武田薬品工業株式会社 複素環化合物
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
British Journal of Pharmacology，2017年，174(5)，396-408
REGISTRY（STN）[online]，2013年06月05日，CAS登録番号 1434337-76-4， ４－フェニル－１－［３－（４Ｈ－１，２，４－トリアゾール－４－イル）ベンゾイル］－４－ピペリジンカルボニトリル
REGISTRY（STN）[online]，2013年09月20日，CAS登録番号 1452797-48-6， ４－フェニル－１－［［２－（４－ピリジニル）－５－ピリミジニル］カルボニル］－４－ピペリジンカルボニトリル
REGISTRY（STN）[online]，2014年06月06日，CAS登録番号 1609743-80-7， ４－フェニル－１－［４－（１Ｈ－ピラゾール－３－イル）ベンゾイル］－４－ピペリジンカルボニトリル
REGISTRY（STN）[online]，2014年06月06日，CAS登録番号 1609750-33-5， ４－フェニル－１－［［２－（４Ｈ－１，２，４－トリアゾール－４－イル）－４－ピリジニル］カルボニル］－４－ピペリジンカルボニトリル
REGISTRY（STN）[online]，2014年06月06日，CAS登録番号 1609792-20-2， １－［３－（１Ｈ－イミダゾール－２－イル）ベンゾイル］－４－フェニル－４－ピペリジンカルボニトリル
REGISTRY（STN）[online]，2017年08月04日，CAS登録番号 2108621-36-7，１－［３－（１－メチル－１Ｈ－イミダゾール－２－イル）ベンゾイル］－４－フェニル－４－ピペリジンカルボニトリル

Also Published As

Publication number Publication date
TWI855081B (zh) 2024-09-11
AR119010A1 (es) 2021-11-17
US20220332699A1 (en) 2022-10-20
MA56032A (fr) 2022-04-06
WO2020243027A1 (en) 2020-12-03
TW202110824A (zh) 2021-03-16
JP2022533436A (ja) 2022-07-22
TW202523658A (zh) 2025-06-16
EP3976186A1 (en) 2022-04-06
JP2025090698A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
JP7687964B2 (ja) 化合物、組成物、および使用方法
JP6388991B2 (ja) キナーゼ阻害剤としてのアミノヘテロアリールベンズアミド
TWI756482B (zh) 治療活性化合物及其使用方法
TWI911340B (zh) 雜芳基甲醯胺化合物
DK2922850T3 (en) Compounds and Methods for Their Use
JP2026048719A (ja) Ｔｒｐｍｌモジュレーター
AU2021237841A1 (en) Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors
JP6964576B2 (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
JP6931003B2 (ja) キノリン−２−オン誘導体
BR112020025642A2 (pt) compostos heterocíclicos como inibidores da monoacilglicerol lipase
TW202115081A (zh) 抗流感病毒化合物及其製備方法和用途
AU2020204341A1 (en) Naphthyridinone derivatives and their use in the treatment of arrhythmia
KR20240038996A (ko) 코로나바이러스 관련 질환의 치료를 위한 화합물 및 조성물
TW202024051A (zh) 苯氧基－吡啶基－嘧啶化合物及使用方法
US20230312522A1 (en) Cyp46a1 inhibitors and methods of use thereof
EP3010916B1 (en) 1,3-diaminocyclopentane carboxamide derivatives
KR102528255B1 (ko) 디아실글리세롤 아실트랜스퍼라제 2 억제제로서 유용한 신규 아미노 아릴 유도체 및 이의 용도
EP2524912A1 (en) Amine derivatives
RU2799819C1 (ru) Новое аминоарильное производное, пригодное в качестве ингибитора диацилглицеролацилтрансферазы 2, и его применение
CN117715898A (zh) 六元芳基或杂芳基酰胺类化合物及其组合物和用途
TW202611041A (zh) 化合物、組合物及其方法
TW202317531A (zh) 六員芳基或雜芳基醯胺類化合物及其組合物和用途
OA21241A (en) Substituted tetrahydrofurans as modulators of sodium channels.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250423

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250522

R150 Certificate of patent or registration of utility model

Ref document number: 7687964

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150